From Grafa:
Paradigm Biopharmaceuticals is currently conducting a global, Phase 3 clinical trial for its iPPS treatment for osteoarthritis (OA).In this interview, Paradigm Biopharmaceuticals Managing Director Paul Rennie discusses the potential for the company’s breakthrough treatment to break into the $8.28 billion global market for osteoarthritis therapeutics. Paradigm has cashed up, having raised $30.1 million in October last year to develop its iPPS treatment for the disease.
https://grafa.com/news/paradigm-biopharmaceuticals--asx-par--conducting-phase-3-osteoarthritis-trial-179958
From Grafa:Paradigm Biopharmaceuticals is currently conducting a...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.010(3.45%) |
Mkt cap ! $97.94M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 28.0¢ | $40.10K | 140.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 135929 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 20969 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |